Itaxel versus weekly paclitaxel alone within the second-line treatment of HER2 amplified advanced gastric cancer (AGC) in Asian population: Tytan study [abstract]. J Clin Oncol 2012(suppl 34):11. http://asco.org/. 31. Hecht JR, Bang Y, Qin S, Chung H, Xu J, Park J, Jeziorski K, Shparyk Y, Hoff PM, Sobrero AF, et al: Lapatinib in mixture with capecitabine plus oxaliplatin in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: The TRIO-013/LOGiC Trial [abstract]. J Clin Oncol 2013(Suppl 31):LBA4001. http://asco.org/. 32. Han SW, Oh DY, Im SA, Park SR, Lee KW, Song HS, Lee NS, Lee KH, Choi IS, Lee MH, et al: Phase II study and biomarker analysis of cetuximab combined with modifi ed FOLFOX6 in sophisticated gastric cancer. Br J Cancer 2009, 100(two):298?04. 33. Moehler M, Mueller A, Trarbach T, Lordick F, Seufferlein T, Kubicka S, Geissler M, Schwarz S, Galle PR, Kanzler S: German Arbeitsgemeinschaft Internistische Onkologie. Cetuximab with irinotecan, folinic acid and 5-fl uorouracil as fi rst-line therapy in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study. Ann Oncol 2011, 22(six):1358?366.34. Lordick F, Luber B, Lorenzen S, Hegewisch-Becker S, Folprecht G, W l E, Decker T, Endlicher E, R hling N, Schuster T, et al: Cetuximab plus oxaliplatin/leucovorin/5-fl uorouracil in first-line metastatic gastric cancer: a phase II study from the Arbeitsgemeinschaft Internistische Onkologie (AIO).887144-94-7 Chemscene Br J Cancer 2010, 102(three):500?05. 35. Kim C, Lee JL, Ryu MH, Chang HM, Kim TW, Lim HY, Kang HJ, Park YS, Ryoo BY, Kang YK: A prospective phase II study of cetuximab in mixture with XELOX (capecitabine and oxaliplatin) in sufferers with metastatic and/or recurrent sophisticated gastric cancer. Invest New Drugs 2011, 29(2):366?73. 36. Lordick F, Kang YK, Chung HC, Salman P, Oh SC, Bodoky G, Kurteva G, Volovat C, Moiseyenko VM, Gorbunova V, et al: Capecitabine and cisplatin with or without the need of cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol 2013, 14(6):490?99. 37. Waddell T, Chau I, Cunningham D, Gonzalez D, Okines AF, Okines C, Wotherspoon A, Saffery C, Middleton G, Wadsley J, et al: Epirubicin, oxaliplatin, and capecitabine with or without having panitumumab for patients with previously untreated sophisticated oesophagogastric cancer (REAL3): a randomised, open-label phase three trial. Lancet Oncol 2013, 14(6):481?89. 38. Ferrara N, Gerber HP, LeCouter J: The biology of VEGF and its receptors. Nat Med 2003, 9(6):669?76. 39. Gerber HP, Ferrara N: Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 2005, 65(3):671?80. 40. Kim SE, Shim KN, Jung SA, Yoo K, Lee JH: The clinicopathological significance of tissue levels of hypoxia-inducible factor-1alpha and vascular endothelial development element in gastric cancer.Price of 2-Bromo-5-cyclopropylpyrimidine Gut Liver 2009, three(two):88?4.PMID:33527733 41. Maeda K, Chung YS, Ogawa Y, Takatsuka S, Kang SM, Ogawa M, Sawada T, Sowa M: Prognostic worth of vascular endothelial development element expression in gastric carcinoma. Cancer 1996, 77(5):858?63. 42. Song ZJ, Gong P, Wu YE: Relationship amongst the expression of iNOS, VEGF, tumor angiogenesis and gastric cancer. Globe J Gastroenterol 2002, eight(4):591?95. 43. Shah MA, Ramanathan RK, Ilson DH, Levnor A, D’Adamo D, O’Reilly E, Tse A, Trocola R, Schwartz L, Capanu M, et al: Multicenter phase II study of irinot.
